Jemperli Wins Accelerated FDA Approval in Locally Advanced Rectal Cancer
GSK’s Jemperli has cleared an important regulatory hurdle in rectal cancer, earning accelerated FDA approval for adults with stage II or III locally advanced disease that carries the MSI-H or dMMR genetic signature. The decision expands a drug first approved for endometrial cancer and gives oncologists a new option in a setting where standard care has usually meant chemotherapy, radiation, and surgery.
The label expansion matters because the approved population is biologically distinct from the broader rectal cancer population. MSI-H and dMMR tumors have defective DNA repair machinery, so they accumulate mutations and can appear more visible to the immune system once the PD-1 brake is removed. Dostarlimab, the drug’s generic name, is a checkpoint inhibitor designed to block PD-1 and allow T cells to recognize and attack cancer cells more effectively.
A single sentence captures the change in practice: some eligible patients may now avoid the most morbid parts of rectal cancer treatment.
Why the MSI-H and dMMR Signal Changed the Treatment Equation
Rectal cancer treatment has traditionally relied on local and systemic therapy before surgery, especially for patients with advanced-stage disease. Chemotherapy and radiation can improve disease control, but they also bring a long list of toxicities and can leave lasting effects on bowel, sexual, and urinary function. For many patients, the prospect of surgery comes with its own functional consequences, including permanent ostomy in some cases.
The appeal of immunotherapy in this genetic subset is straightforward. Tumors with mismatch repair deficiency tend to harbor abundant neoantigens because they cannot repair DNA damage efficiently. Once PD-1 is blocked, immune cells can mount a stronger antitumor response, and in some patients that response is deep enough to eliminate detectable disease without the need for multimodal treatment. In a disease where anatomic preservation and quality of life matter as much as tumor control, that mechanism carries real bedside consequences.
Eligibility is narrow and depends on molecular testing. Before a patient can receive Jemperli for this indication, the tumor must be shown to be MSI-H or dMMR by an FDA-authorized test for solid tumors. That requirement keeps the therapy anchored to the subgroup most likely to benefit and prevents extrapolation to biologically different rectal cancers.
Phase 2 Data Drove the Regulatory Review
The FDA decision rests on interim results from a pivotal Phase 2 study in 154 previously untreated rectal cancer patients. After a median follow-up of more than two years, almost three-fourths of patients had not required surgery, radiation, or chemotherapy. Those are the treatment milestones that usually define the standard pathway in locally advanced rectal cancer, so avoiding them represents a substantial departure from conventional care.
Earlier experience with the drug in this disease type built the momentum for approval. A small study at Memorial Sloan Kettering Cancer Center first drew attention when every one of 50 patients treated with Jemperli alone had no detectable signs of cancer, and 93% remained cancer free at one year. Those findings helped establish the possibility that a subset of rectal cancers with defective mismatch repair may be especially susceptible to PD-1 blockade before they ever reach the operating room.
The biology fits the response pattern. In MSI-H or dMMR disease, immune activation is not merely theoretical; it can translate into complete clinical and radiographic clearance in a portion of patients. When that happens, the traditional sequence of neoadjuvant chemoradiation followed by surgery can become unnecessary, at least for some patients during the period observed so far.
Accelerated Approval Means the Data Still Need to Mature
The FDA used accelerated approval, which is reserved for situations where an earlier regulatory decision is justified by a likely surrogate for clinical benefit. In this case, the interim response data were enough to support approval, but GSK must still provide additional evidence showing durable benefit. The label is therefore real and actionable, yet still dependent on follow-up that will determine how long responses hold and how often patients eventually need other therapy.
Speed mattered in the review process as well. Jemperli was evaluated under an FDA pilot program intended to shorten review times for drugs that address national health interests, including cancers with limited treatment options. The result is a faster path to the clinic, but not a shortcut around evidence generation.
Durability is the central unanswered clinical issue. A response that holds for two years is meaningful, but rectal cancer is not a disease clinicians can judge on short snapshots alone. Local regrowth, delayed need for surgery, and late toxicity patterns all matter, and ongoing follow-up will determine whether this immunotherapy strategy can reliably replace established multimodality treatment for a larger share of patients.
Commercial Momentum and Broader Development Plans
Jemperli has become GSK’s top cancer product, and the company sees room to expand its use beyond endometrial and rectal cancer. The drug was initially discovered and developed by AnaptysBio, later licensed to Tesaro, and GSK continued development after acquiring Tesaro in 2018. Since its 2021 approval in endometrial cancer, revenue has climbed sharply, with GSK reporting £861 million in 2025 sales and £480 million in the first half of this year.
Those numbers reflect more than a successful product launch. They show how a biomarker-defined immunotherapy can move from a niche approval into a broader oncology franchise when the biology is strong and the clinical signal is clear. Clinical trials are already underway in colorectal and head and neck cancers, extending the same PD-1 strategy into other tumors where immune evasion and DNA repair defects may create a therapeutic opening.
For now, the rectal cancer approval stands on a specific molecular foundation, not a class-wide assumption. The benefit is confined to adults with locally advanced stage II or III disease that is MSI-H or dMMR, and the therapy still requires confirmatory follow-up for full clinical credibility. Patients may gain a path away from chemotherapy, radiation, and surgery, but the long-term durability of that path is still being measured.